Collectively, the NMD inhibition strategy could benefit approximately 6% of all cancers, which bear the appropriate p53 mutations and MDM2 amplification (MDM2 amplified, 3.7%; and mutations downstream of exon 9, 2.7%: Tables S1 and S3). The gene discussed is TP53; the disease is cancer.